CClinicalTrials.gg
CompletedNCT02366598Updated Mar 17, 2023

A FINEH Protein Trial - Part 1

An interventional study of Hemp shake and Soybean shake in Diabetes Prevention and Obesity Prevention, sponsored by University of Manitoba. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-17.

Sponsored by University of Manitoba · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objectives of this trial are to assess the health benefits of acute hemp protein consumption compared to soybean protein and a non-protein control on: 1) blood glucose, appetite and blood pressure for one hour following consumption, 2) food intake at an ad libitum meal one hour following consumption and 3) blood glucose, appetite and blood pressure following the ad libitum meal to determine the "second meal effect" of hemp protein.

02

Conditions studied

  • Diabetes Prevention
  • Obesity Prevention
03

In context

Lead sponsor

University of Manitoba is the lead sponsor of 542 studies on the registry; 87 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Normoglycemic (\<5.6 mmol/L)
  • Body mass index (BMI) of 18.5-29.9 kg/m2 Participants will be excluded if they regularly skip breakfast, smoke, or consuming medications that may influence study outcomes or have experienced any gastrointestinal related health conditions/surgeries over the past year.

Exclusion criteria

Exclusion Criteria:

  • Restrained eaters
  • Regularly skip breakfast
  • Smokers
  • Those who are active (organized activities or athletic training at a high intensity; ≥ 150 min per week of moderate to vigorous physical activity)
  • Those on medications that may influence study outcomes or have experienced any gastrointestinal related health conditions/surgeries over the past year.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    20g Hemp protein shake

    Hemp protein shake, 20 grams, given once at beginning of acute trial

    Other: Hemp shake

  • Experimental
    40 g hemp protein shake

    Hemp protein shake, 40 grams, given once, at beginning of acute trial

    Other: Hemp shake

  • Active comparator
    20 g Soybean protein shake

    Soybean protein shake, 20 grams, given once, at beginning of acute trial

    Other: Soybean shake

  • Experimental
    40 g Soybean protein shake

    Soybean protein shake, 40 grams, given once, at beginning of acute trial

    Other: Soybean shake

  • Placebo comparator
    Control shake

    non-protein control shake, given once, at beginning of acute trial

    Other: Control

Interventions

  • OtherHemp shake

    Hemp protein shake

  • OtherSoybean shake

    Soybean protein shake

  • OtherControl

    Non-protein shake

06

What researchers measure

Primary outcomes

  1. Blood glucose concentration

    Measured in blood by glucometer

    Time frame: 0-200 min

  2. Appetite

    Measured by VAS Questionnaire

    Time frame: 0-200 min

  3. Food intake

    Ad-libitum meal

    Time frame: 0-200 min

  4. Blood pressure

    Measured by automated bood pressure cuff

    Time frame: 0-200 min

Secondary outcomes

  1. Palatability of treatments and meal

    Measured by VAS questionnaire

    Time frame: 5 -80 minutes

  2. Physical comfort

    Measured by VAS questionnaire

    Time frame: 0 - 200 min

  3. Energy/fatigue

    Measured by VAS questionnaire

    Time frame: 0 - 200 min

07

Study locations

1 site
  • Richardson Centre for Functional Foods
    Winnipeg, Manitoba R3T2N2, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02366598
Lead sponsor
University of Manitoba
Collaborators
Manitoba Harvest
Responsible party
Sponsor
First posted
Feb 19, 2015
Start date
May 2015
Primary completion
Dec 2015
Completion
Sep 2017
Last update
Mar 17, 2023

Study contacts

Peter JH Jones, PhD
principal investigator · University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion